Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. - Wikidata - wikimedia - TriplyDB

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

http://www.wikidata.org/entity/Q35954116

about

Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Biological Treatments in Atopic Dermatitis Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease Therapeutic drug monitoring in inflammatory bowel disease Review article: anti-adhesion therapies for inflammatory bowel disease Infliximab-Related Infusion Reactions: Systematic Review Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Use of the tumor necrosis factor-blockers for Crohn's disease Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Review article: dose optimisation of infliximab for acute severe ulcerative colitis.Pharmacokinetic characteristics of therapeutic antibodies.Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Combination therapy for inflammatory bowel disease Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.European evidence-based Consensus on the management of ulcerative colitis: Current management.Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.Current status of thiopurine analogues in the treatment in Crohn's disease.Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease Methotrexate for Inflammatory Bowel Diseases - New Developments Infliximab in the treatment of plaque type psoriasis.Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group The development and assessment of biological treatments for children.Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.Infliximab to treat Crohn's disease: an update.Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.Biologics in paediatric Crohn's disease.Effectiveness and risk associated with infliximab alone and in combination with immunosuppressors for Crohn's disease: a systematic review and meta-analysis Combination therapy for the treatment of Crohn's disease.Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease Specialized enteral nutrition therapy in Crohn's disease patients on maintenance infliximab therapy: a meta-analysis.Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.

P2860

Q24185835-F5230AF3-75A9-4DB1-85E0-013C14555802 Q26745721-D88346D1-3D3F-4E05-B310-D955B8973EF0 Q26777409-862042A3-D12D-4158-9FF6-81EA24375D9E Q26799579-317CC858-18F7-412E-A4A5-19F3F439FB52 Q26827444-24539171-6E56-44B8-BB73-B04AFFFDA599 Q26852729-5D8EA1FF-D505-44AE-8334-3514E62E9046 Q26999705-6B22666F-10EA-4016-B7CD-572144BFCB28 Q27013835-3B8628F4-D8D5-4A70-A479-4245B3E8FD9E Q27021612-9C1D5E31-C763-40DD-928B-35EF836EBAA6 Q27030762-7442F4F5-FB7D-408C-B8E0-C48A87094011 Q28066776-F7806651-D399-4134-839C-467D5E550595 Q28079644-0A54CBA5-3077-4D5E-B7B5-F9B2A636531E Q28088683-7EB54758-93EF-4C4A-B10D-8D3BA601C09B Q30235581-AB0A6E12-5FC5-44BA-81B4-449F3894DCA0 Q30239077-C28973D0-EC9C-41F2-84AB-4301C96C1670 Q30316517-C3398478-E6E4-4BD7-B2E1-E18E7313DB62 Q30412650-79868432-174C-4924-A5A9-ECDB3A02FF13 Q30995889-EAFFD1C1-7F2D-45DD-9715-CC01F5C03E6B Q33646452-D0DDF0EB-C0A4-45F6-97AF-28E414D1990A Q33874790-4C282FE9-97AC-42A2-8664-98F4E3EC1940 Q34025054-A28B35E2-044D-4496-BD32-F4AD0500FE2E Q34047653-3FDF7461-96E4-4519-B1CF-457F2960828E Q34152778-42906912-1E2E-40D0-AC69-B73AEC93F5BB Q34235370-093AB8D5-AC5D-4AD0-A862-B4B97134E075 Q34449843-EC8FF134-11DD-42DE-95F1-6669F7973B57 Q34518393-5E93D5DB-F0A7-4766-8433-CFF217EF1C6C Q34620291-C819E124-C6C5-4C6A-AA18-85A9B330B041 Q35013983-2F40B60D-BECA-4A6F-9A64-3038AB5C1B1A Q35135936-8573B5D4-5FB3-46CA-8092-2342A97F2697 Q35193565-C2954498-F22C-4D63-9822-7A569957F63E Q35213972-780B18A0-108B-4CC4-B555-7B0CCFB7D4E7 Q35304737-6CF35183-13CA-43B2-BBF1-01F1D8849319 Q35547487-6CBD51AF-C089-4F36-A301-560CFF0638E8 Q35579308-EFFD2852-0631-477B-B4C2-2CBA000B65B7 Q35679414-36C94B13-1369-4287-9535-CFAFA89D152F Q35714202-16AD31C7-4832-42B2-8F02-5D310849DCB9 Q35763489-98347F4F-86D4-4ED3-BBA4-ACDF7C14B2D4 Q35780904-1AB67697-3DC7-411B-ACBA-9BF877B73BEC Q36193973-5A9BC7FF-0E13-4AE8-980D-0455852C810D Q36209653-E8E9C6B7-D6AC-428A-ACC8-4178CB2DFAB2

P2860

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

http://www.wikidata.org/entity/Q35954116

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Effectiveness of concomitant i ...... infliximab in Crohn's disease.

@ast

Effectiveness of concomitant i ...... infliximab in Crohn's disease.

@en

type

label

Effectiveness of concomitant i ...... infliximab in Crohn's disease.

@ast

Effectiveness of concomitant i ...... infliximab in Crohn's disease.

@en

prefLabel

Effectiveness of concomitant i ...... infliximab in Crohn's disease.

@ast

Effectiveness of concomitant i ...... infliximab in Crohn's disease.

@en

P1433

Q35954116-ECDCF380-4D75-403A-BC30-72FEB3D7C1FC

P1476

Q35954116-7A97B98B-42FA-495E-AD4B-3C32674FA643

P2093

Q35954116-119072DA-32D4-4056-A562-7850F011C2E2

Q35954116-561EB6D5-A346-4A1D-9EEE-B104B6D536AD

Q35954116-A8F77F89-90CE-4782-97A6-587DCB0B14BB

P2860

Q35954116-15281C10-755B-4647-9F52-88876ABA2437

Q35954116-41A4F033-196C-465D-90AD-EC543FA4D69D

Q35954116-73339597-F1C7-49E8-8C49-F49D1741C141

Q35954116-78DED4B4-E892-453C-9EF2-42A8697F3463

Q35954116-7C6A9DEF-EFEF-4C06-85A0-4B6E1D3C05E6

Q35954116-7E685A80-2184-4E3E-B58D-75CA64F7222F

Q35954116-80726AA9-10B0-4EC6-A4A1-6E0E07560A1D

Q35954116-84325858-B820-40C6-BAC3-FDB2B477E073

Q35954116-885EF8B3-5348-425E-BC26-B7E7526F3503

Q35954116-8BC8CDBA-FEA6-4047-AC0B-3514B94609B4

P304

Q35954116-B8D8A690-BBC8-4C59-A0E5-6D3C51C6E04C

P31

Q35954116-BBD0355B-7C0B-459F-BA80-A75F6BCA4536

P356

Q35954116-0B217E4A-DE1E-49A0-9E6E-8E7F2A6008DF

P407

Q35954116-7CDA064F-5543-40B6-8774-116964C35CEF

P433

Q35954116-EDC523B8-72F6-4FB2-AA1C-8499D185D928

P478

Q35954116-AA41954E-627C-4243-B756-CF72AAF395B3

P50

Q35954116-5F742D10-4D80-477A-B1F9-8FE1F6813021

Q35954116-A5FA523D-87C2-4A48-A7F8-618E9B21ED30

Q35954116-B2585DA7-F416-410F-8B98-4E238BB31FA7

P577

Q35954116-437448E1-61DD-4C58-99E1-FD939846E762

P5875

Q35954116-F192F789-796F-4253-8378-96B0793E2B0C

P698

Q35954116-7AF74CE5-9106-455E-8F2B-EEE0888DF790

P921

Q35954116-4EDACC86-A102-4E01-9EA8-65CD5BECFE6D

Q35954116-D6D23589-CD1E-4C35-9CE7-A0876E4120F8

P932

Q35954116-0909C55E-9396-4DDD-BEE5-5AD2A04063DD

P356

GUT.2006.099978

P1433

P1476

Effectiveness of concomitant i ...... infliximab in Crohn's disease.

@en

P2093

Filip Baert

http://www.w3.org/2001/XMLSchema#string

Maja Noman

http://www.w3.org/2001/XMLSchema#string

Severine Vermeire

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab maintenance therapy for fistulizing Crohn's disease

Infliximab for induction and maintenance therapy for ulcerative colitis

Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group.

Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab.

Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model.

Predictors of response to infliximab in patients with Crohn's disease.

Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial.

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

P304

1226-1231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.2006.099978

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Gert Van Assche

P577

2007-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6572477

http://www.w3.org/2001/XMLSchema#string

P698

17229796

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

P932

1954977

http://www.w3.org/2001/XMLSchema#string